Noah Lechtzin

7.4k total citations · 1 hit paper
116 papers, 4.9k citations indexed

About

Noah Lechtzin is a scholar working on Pulmonary and Respiratory Medicine, Neurology and Genetics. According to data from OpenAlex, Noah Lechtzin has authored 116 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Pulmonary and Respiratory Medicine, 23 papers in Neurology and 21 papers in Genetics. Recurrent topics in Noah Lechtzin's work include Cystic Fibrosis Research Advances (40 papers), Amyotrophic Lateral Sclerosis Research (22 papers) and Neurogenetic and Muscular Disorders Research (18 papers). Noah Lechtzin is often cited by papers focused on Cystic Fibrosis Research Advances (40 papers), Amyotrophic Lateral Sclerosis Research (22 papers) and Neurogenetic and Muscular Disorders Research (18 papers). Noah Lechtzin collaborates with scholars based in United States, Canada and Germany. Noah Lechtzin's co-authors include Gregory B. Diette, Michael Boyle, Christian A. Merlo, Lora Clawson, Charles Wiener, Haya R. Rubin, Reda E. Girgis, Paul M. Hassoun, Stephen C. Mathai and Edward F. Haponik and has published in prestigious journals such as Annals of Internal Medicine, The Journal of Immunology and Neurology.

In The Last Decade

Noah Lechtzin

110 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study

2023 82 citations Steven M. Rowe, Jonathan B. Zuckerman et al. Journal of Cystic Fibrosis profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Noah Lechtzin United States	41	3.1k	718	625	623	612	116	4.9k
Geir Egil Eide Norway	45	1.9k 0.6×	610 0.8×	250 0.4×	243 0.4×	392 0.6×	193	6.3k
Ron Wolterbeek Netherlands	42	1.2k 0.4×	1.2k 1.6×	195 0.3×	886 1.4×	311 0.5×	210	6.2k
Julie A. Stoner United States	40	920 0.3×	689 1.0×	251 0.4×	594 1.0×	144 0.2×	186	5.7k
Benôıt Marin France	35	581 0.2×	442 0.6×	1.6k 2.5×	630 1.0×	923 1.5×	156	5.5k
Gabriele Ihorst Germany	40	758 0.2×	616 0.9×	682 1.1×	110 0.2×	847 1.4×	199	5.8k
T. Pérez France	35	3.0k 1.0×	450 0.6×	484 0.8×	228 0.4×	166 0.3×	155	4.4k
Carlos S. Restrepo United States	36	1.5k 0.5×	634 0.9×	284 0.5×	1.1k 1.7×	128 0.2×	160	4.0k
Michael H Bennett Australia	34	783 0.3×	610 0.8×	375 0.6×	281 0.5×	131 0.2×	128	3.4k
Marco Maggiorini Switzerland	48	2.6k 0.9×	765 1.1×	207 0.3×	1.7k 2.7×	195 0.3×	180	8.3k
Erich W. Russi Switzerland	45	3.7k 1.2×	676 0.9×	142 0.2×	633 1.0×	303 0.5×	174	6.4k

Countries citing papers authored by Noah Lechtzin

Since Specialization

Citations

This map shows the geographic impact of Noah Lechtzin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noah Lechtzin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noah Lechtzin more than expected).

Fields of papers citing papers by Noah Lechtzin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noah Lechtzin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noah Lechtzin. The network helps show where Noah Lechtzin may publish in the future.

Co-authorship network of co-authors of Noah Lechtzin

This figure shows the co-authorship network connecting the top 25 collaborators of Noah Lechtzin. A scholar is included among the top collaborators of Noah Lechtzin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noah Lechtzin. Noah Lechtzin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kronenberg, Amy, Elizabeth W. Tucker, Joel S. Freundlich, et al.. (2025). Dynamic 11C– Para –Aminobenzoic Acid Positron Emission Tomography/Computed Tomography for Visualizing Pulmonary Mycobacteroides abscessus Infections. American Journal of Respiratory and Critical Care Medicine. 211(7). 1253–1263.

Hoppe, Jordana E., J Sjöberg, Gina Hong, et al.. (2024). Remote endpoints for clinical trials in cystic fibrosis: Report from the U.S. CF foundation remote endpoints task force. Journal of Cystic Fibrosis. 23(4). 725–733. 3 indexed citations

Hunt, William B., et al.. (2024). 741 Expanded use of remote objective monitoring during telehealth visits for people with CF experiencing acute symptoms: the EUROPA Study. Journal of Cystic Fibrosis. 23. S421–S421. 1 indexed citations

Rowe, Steven M., Jonathan B. Zuckerman, Daniel Dorgan, et al.. (2023). Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study. Journal of Cystic Fibrosis. 22(4). 656–664. 82 indexed citations breakdown →

Meng, Lisa, Stacy A. Rudnicki, Andrew A. Wolff, et al.. (2023). Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS. Journal of Medical Economics. 26(1). 488–493. 2 indexed citations

Meng, Lisa, Stacy A. Rudnicki, Andrew A. Wolff, et al.. (2022). MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 24(3-4). 304–310. 3 indexed citations

Smith, Lauren, Ana‐Maria Orbai, Jemima Albayda, et al.. (2022). Snap, Crackle, and Pop: From a Painful Finger to Progressive Dyspnea to Popping Neck Pain. The American Journal of Medicine. 136(2). 143–146.

Hansen, Ryan N., et al.. (2021). Health care costs related to home spirometry in the eICE randomized trial. Journal of Cystic Fibrosis. 21(1). 61–69. 4 indexed citations

Braun, Andrew T., Candela Caballero‐Eraso, & Noah Lechtzin. (2018). Amyotrophic Lateral Sclerosis and the Respiratory System. Clinics in Chest Medicine. 39(2). 391–400. 18 indexed citations

10.

Lechtzin, Noah, Nicole Mayer-Hamblett, Natalie E. West, et al.. (2017). Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results. American Journal of Respiratory and Critical Care Medicine. 196(9). 1144–1151. 86 indexed citations

11.

Hassoun, Paul M., Roham T. Zamanian, Rachel L. Damico, et al.. (2015). Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 192(9). 1102–1110. 114 indexed citations

12.

Lechtzin, Noah, et al.. (2010). A Randomized Trial of Nature Scenery and Sounds Versus Urban Scenery and Sounds to Reduce Pain in Adults Undergoing Bone Marrow Aspirate and Biopsy. The Journal of Alternative and Complementary Medicine. 16(9). 965–972. 73 indexed citations

13.

Campo, Arantza, Stephen C. Mathai, Jérôme Le Pavec, et al.. (2010). Hemodynamic Predictors of Survival in Scleroderma-related Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 182(2). 252–260. 168 indexed citations

14.

Dasenbrook, Elliott C., Christian A. Merlo, Noah Lechtzin, & Michael Boyle. (2009). The Impact of MRSA on Lung Function in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 179(8). 735–735. 2 indexed citations

15.

Pipeling, Matthew R., Erin E. West, Christine Osborne, et al.. (2008). Differential CMV-Specific CD8+ Effector T Cell Responses in the Lung Allograft Predominate over the Blood during Human Primary Infection. The Journal of Immunology. 181(1). 546–556. 32 indexed citations

16.

Dasenbrook, Elliott C., Christian A. Merlo, Marie Diener‐West, Noah Lechtzin, & Michael Boyle. (2008). Persistent Methicillin-resistant Staphylococcus aureus and Rate of FEV1 Decline in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 178(8). 814–821. 253 indexed citations

17.

Shlobin, Oksana A., Erin E. West, Noah Lechtzin, et al.. (2006). Persistent Cytomegalovirus-Specific Memory Responses in the Lung Allograft and Blood following Primary Infection in Lung Transplant Recipients. The Journal of Immunology. 176(4). 2625–2634. 51 indexed citations

18.

Boyle, Michael, et al.. (2005). Failure of High-Dose Ergocalciferol to Correct Vitamin D Deficiency in Adults with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 172(2). 212–217. 70 indexed citations

19.

Lechtzin, Noah, Haya R. Rubin, Peter White, Mollie W. Jenckes, & Gregory B. Diette. (2002). Patient Satisfaction with Bronchoscopy. American Journal of Respiratory and Critical Care Medicine. 166(10). 1326–1331. 73 indexed citations

20.

Lechtzin, Noah, Haya R. Rubin, Mollie W. Jenckes, et al.. (2000). Predictors of Pain Control in Patients Undergoing Flexible Bronchoscopy. American Journal of Respiratory and Critical Care Medicine. 162(2). 440–445. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact